MedTrace Logo

Studying the Efficacy of Aspirin & Clopidogrel in Healthy Subjects With Stable Coronary Artery Disease.

NCT01011257 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2018-01-31

No results posted yet for this study

Summary

The investigators will test the hypothesis that aspirin or clopidogrel taken twice daily will augment their antiplatelet efficacy in patients with an elevated platelet turnover (as measured by the proportion of reticulated (young) platelets) compared with once daily dosing.

Conditions

Interventions

DRUG

Asprin

asprin 81mg, 1 tab, twice daily OR aspirin 81mg, 2 tab, once daily

DRUG

Clopidogrel

clopidogrel 75 mg bid

Sponsors & Collaborators

  • Neil Kleiman, MD

    lead OTHER

Principal Investigators

  • Neal S Kleiman, MD · Methodist DeBakey Heart Center.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-08-31
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01011257 on ClinicalTrials.gov